This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼(isatuximab) can be found via the Product Card at the bottom of the page.
Relapsed Refractory Multiple Myeloma Product
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
MAT-XU-2202574 (v2.0) Date of preparation: December 2023